Thus, our study revealed that NRF2 drives the expression of genes involved in glutathione metabolism, so the development of NRF2 inhibitors could be a means of altering tumor growth and drug resistance in HNSCC. Here, NFE2L2 is linked to head and neck squamous cell carcinoma.